1Q24 Investor Update

● 01 F2024 STRATEGIC HIGHLIGHTS Completed planting first seed-based production grow room resulting from strategic investment in US-based Phylos • Advanced the second tranche of US$2.75 million to Phylos for a total current investment of US$6.0 million in senior secured convertible loans due to early achievement of THCV concentration and aroma milestones for F1 seeds • Completed first craft harvest resulting from the completed expansion of the Company's Lac-Supérieur facility • Product Development Collaboration with BAT moving rapidly toward product commercialization. PK study for nano-emulsion gummy technology complete and the Company is compiling and analyzing results to substantiate product claims. regarding onset and half-life • Applied for EU-GMP certification of Moncton facility in November 2023 and awaiting audit • Subsequent to Q1 F2024 announced shareholder approval and closing of first $41.5 million tranche of $124.6 million follow-on investment from BAT and creation of the Jupiter investment pool to increase Organigram's international footprint ORGANIGRAM BAT A BETTER TOMORROW afo PHYLOS BIOSCIENCE GREENTANK

View entire presentation